<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="21, 28, 29, 30, 31, 32, 40, 44, 50] and" exact="New Zealand" post="(n = 2) [ 34, 41]), with 13 from"/>
 <result pre="26, 27, 35, 36, 37, 38, 42, 43, 46, 49]," exact="Canada" post="(n = 1) [ 47]) and 8 from Europe"/>
 <result pre="Europe (UK (n = 4) [ 20, 33, 39, 48]," exact="Germany" post="(n = 2) [ 51, 52], Finland (n ="/>
 <result pre="33, 39, 48], Germany (n = 2) [ 51, 52]," exact="Finland" post="(n = 1) [ 54], Spain (n = 1)"/>
 <result pre="2) [ 51, 52], Finland (n = 1) [ 54]," exact="Spain" post="(n = 1) [ 53]). Only one study was"/>
 <result pre="42, 43, 46, 47, 49], and the only study from" exact="China" post="[ 45] conducted a CEA only. Across Europe, only"/>
 <result pre="33, 39, 48], compared to most of those conducted within" exact="Australia" post="and the USA, applied a societal perspective. Two studies"/>
 <result pre="the relevant country guidelines apart from one prevention trial from" exact="New Zealand" post="[ 41], which used a 5% discount rate per"/>
 <result pre="rate for both costs and outcomes (3% per year for" exact="Australia" post="(n = 12) [ 12, 28, 29, 30, 31,"/>
 <result pre="(n = 1) [ 39], and 3.5% per year for" exact="New Zealand" post="(n = 1) [ 34]. Interestingly, the rates used"/>
 <result pre="1) [ 34]. Interestingly, the rates used for studies from" exact="Australia" post="and the UK were not in accordance with their"/>
 <result pre="their respective country guidelines (which is 5% per year for" exact="Australia" post="according to PBAC and 3.5% per year for the"/>
 <result pre="to NICE) [ 56, 57]. However, different state governments in" exact="Australia" post="recommend different rates and the discount rate used in"/>
 <result pre="32, 40, 42, 46, 50, 52], these were mainly from" exact="Australia" post="(n = 5) and most of them were for"/>
 <result pre="direct non-medical costs were reported by four prevention studies from" exact="Australia" post="[ 29, 32, 40, 50] and one treatment study"/>
 <result pre="pay of £20,000–30,000 per QALY [ 63], by contrast in" exact="Australia" post="the recommendation is AU$50,000 per QALY [ 29] and"/>
 <result pre="outcomes (e.g., anthropometric measurements [ 13]). Two additional reviews from" exact="Australia" post="[ 12] and the US [ 15] used the"/>
 <result pre="of a School-Based Comprehensive Intervention Study on Childhood Obesity in" exact="China" post="PLoS ONE 2013 8 e77971 10.1371/journal.pone.0077971 24205050 46. Epstein"/>
 <result pre="for Cost-utility Analysis Version 2.2 PHARMAC Pharmaceutical Management Agency Wellington," exact="New Zealand" post="2015 56. collab: Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines"/>
 <result pre="Version 4.3 Australian Government Department of Health and Ageing Canberra," exact="Australia" post="2008 57. collab: NICE Methods for the Development of"/>
</results>
